- Fellowship - Stanford University Hospital (1983-1985), Gynecologic Oncology
- Fellowship - University of California at San Diego (1981-1982), Gynecologic Oncology
- Residency - Medical College of Pennsylvania (1978-1981), Obstetrics & Gynecology
- Internship - Medical College of Pennsylvania (1977-1978), Obstetrics & Gynecology
- Medical School - University of Oklahoma at Tulsa
David Scott Miller, M.D.
- Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
- Dallas Foundation Chair in Gynecologic Oncology
- Obstetrics & Gynecology - Gyn Oncology
- Gynecologic Cancers
- Surgical Treatment for Gynecologic Cancer
David Scott Miller, M.D., is a Professor in the Department of Obstetrics and Gynecology at UT Southwestern Medical Center. He specializes in cancers of the female reproductive system and serves as chief of the Division of Gynecologic Oncology, leading the team of gynecologic oncologists at UT Southwestern. In addition, he is Medical Director for the division’s practice at the Harold C. Simmons Comprehensive Cancer Center and Medical Director for gynecologic oncology at Parkland Health and Hospital System.
Dr. Miller earned his medical degree at the University of Oklahoma–Tulsa and completed a residency in obstetrics and gynecology at the Medical College of Pennsylvania. He received advanced training through a reproductive endocrinology fellowship at the University of California, San Diego and a gynecologic oncology fellowship at Stanford University Medical Center.
Board certified in obstetrics and gynecology and gynecologic oncology, he joined the UT Southwestern faculty in 1991.
Dr. Miller serves as principal investigator for the National Cancer Institute’s Gynecologic Oncology Group program at UT Southwestern. He also is an examiner for the American Board of Obstetrics and Gynecology, where he participates in the oral examination of physicians seeking certification as specialists in gynecologic oncology.
Dr. Miller’s research interests include reconstructive pelvic surgery, gynecologic oncology, and clinical trials. He has published several academic articles.
He is frequently included in D Magazine’s list of Best Doctors in Dallas and as a Super Doctor in Texas Monthly magazine.
Dr. Miller is a member of the Society of Gynecologic Oncology, the American Society of Clinical Oncology, the American College of Obstetricians and Gynecologists, and the American College of Surgeons.
Meet Dr. Miller
Gynecologic Oncology Specialist in Dallas
Early in his career, David Scott Miller, M.D., decided that his mission was helping women with their journey through cancer. He believes that no matter what the cancer diagnosis is, it brings a sense of urgency and clarity. That belief is part of the driving force behind his nationally and internationally recognized work to improve the evaluation and treatment of gynecologic cancers.
"When and where the cancer is diagnosed will have an impact on a woman’s chances of surviving the disease. It’s extremely important to have one doctor trained in all aspects of evaluating and treating gynecologic cancer committed to the patient," he says.
Since joining UT Southwestern Medical Center in 1991, Dr. Miller has assembled a team focused completely on gynecologic cancers. This team includes faculty physicians – trained and board certified in obstetrics and gynecology – who have gone on to complete fellowship training in gynecologic oncology. They are experts in gynecology and the cancers that affect the female reproductive organs and are passionate about caring for women with gynecologic cancer.
Cancers affecting a woman’s reproductive system, including the ovaries, uterus, cervix, vagina, vulva, and placenta, can be complex. Dr. Miller and his team bring a comprehensive approach to care that offers patients unique access to the newest diagnostic procedures, innovative therapies and surgical care, exceptional support services, and groundbreaking research and clinical trials.
An advocate of providing the newest options to patients, Dr. Miller says UT Southwestern is on the leading edge of surgical and medical innovations to eliminate gynecologic cancer. These innovations include state-of-the-art minimally invasive and robotic procedures to remove tumors, fertility-sparing procedures, and targeted therapies to attack cancer cells without damaging noncancerous tissue.
Dr. Miller serves as a principal investigator for the National Cancer Institute’s Gynecologic Oncology Group and participates in the cancer evaluation and treatment protocols developed by that organization. UT Southwestern is also the only institution in North Texas that is a member of the National Institutes of Health’s (NIH) Gynecologic Oncology Group, which is the hub of major research and innovations for gynecologic cancers.
- Society of Gynecologic Oncology
- Gynecologic Oncology Group
- American Society of Clinical Oncology
- American College of Surgeons
- American College of Obstetricians & Gynecologists
- D Best Doctor - Gynecological Oncology, D Magazine - 2012, 2011, 2010
- First Prize Scientific Paper Award 1991, American College of Obstetricians & Gynecologists, 39th Annual Meeting
- Senior Residents Award for Outstanding Faculty Teacher 2000, Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center at Dallas
- National Faculty Award 2000, Council on Resident Education in Obstetrics & Gynecology
- Texas Super Doctors 2011, Texas Monthly
- D Best - Gynecological Oncology 2012, D Magazine Best Doctors 2010, 2011
- Top Doctor - Gynecologic Oncology / Gynecology 2013, U.S. News and World Report
- Super Doctors in Texas - Oncology 2013, Oncology; Obstetrics/Gynecology
Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.
Lavie I, Rao GG, Castrillon DH, Miller DS, Schorge JO American journal of obstetrics and gynecology 2005 May 192 5 1362-4
Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.
Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, Muller CY Reproductive sciences (Thousand Oaks, Calif.) 2007 Jan 14 1 20-8
Implications of EGFR inhibition in ovarian cancer cell proliferation.
Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS Gynecologic oncology 2008 Jun 109 3 411-7
Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Boren TP, Miller DS Women's health (London, England) 2010 Nov 6 6 789-95
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2010 Oct 20 7 1137-41
Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma?
Garcia-Soto AE, Boren T, Wingo SN, Heffernen T, Miller DS American journal of obstetrics and gynecology 2012 Mar 206 3 242.e1-5
Clinical applications of hormonal therapy in ovarian cancer.
Rao GG, Miller DS Current treatment options in oncology 2005 Mar 6 2 97-102
Hormonal therapy in epithelial ovarian cancer.
Rao GG, Miller DS Expert review of anticancer therapy 2006 Jan 6 1 43-7
Somatic LKB1 mutations promote cervical cancer progression.
Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH PloS one 2009 4 4 e5137
Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement.
Boren T, Lea J, Kehoe S, Miller DS, Richardson D Gynecologic oncology 2012 Oct 127 1 43-6
CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors
Bulun, S.E., Economos, K., Miller, D., Simpson, E.R. Journal of Clinical Endocrinology and Metabolism 1994 79 (6) 1831-1834
Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers
Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R, Bowcock AM. Human Molecular Genetics 1998 7 (2) 195-202
Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study
O’Boyle, J.D., Coleman, R.L., Bernstein, S.G., Lifshitz, S., Muller, C.Y., Miller, D.S. Gynecologic Oncology 2000 79 (2) 238-243
Fertility-sparing surgery for ovarian low malignant potential tumors.
Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2005 Aug 98 2 263-6
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC Gynecologic oncology 2005 Aug 98 2 217-21
Ovarian preservation in stage I low-grade endometrial stromal sarcomas.
Li AJ, Giuntoli RL, Drake R, Byun SY, Rojas F, Barbuto D, Klipfel N, Edmonds P, Miller DS, Karlan BY Obstetrics and gynecology 2005 Dec 106 6 1304-8
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Miller DS, Blessing JA, Waggoner S, Schilder J, Sorosky J, Bloss J, Schilder R Gynecologic oncology 2005 Jan 96 1 67-71
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
Long HJ, Bundy BN, Grendys EC, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Jul 23 21 4626-33
Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
Garcia AA, Blessing JA, Lenz HJ, Darcy KM, Mannel RS, Miller DS, Husseinzadeh N Gynecologic oncology 2005 Mar 96 3 810-7
Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
Long HJ, Monk BJ, Huang HQ, Grendys EC, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV Gynecologic oncology 2006 Mar 100 3 537-43
Retrospective cohort study of surgical staging for ovarian low malignant potential tumors.
Wingo SN, Knowles LM, Carrick KS, Miller DS, Schorge JO American journal of obstetrics and gynecology 2006 May 194 5 e20-2
Gestational trophoblastic disease among Hispanic women: a 21-year hospital-based study.
Drake RD, Rao GG, McIntire DD, Miller DS, Schorge JO Gynecologic oncology 2006 Oct 103 1 81-6
Silencing of HPV 18 oncoproteins with RNA interference causes growth inhibition of cervical cancer cells
Lea, J.S., Sunaga, N., Sato, M., Kalahasti, G., Miller, D.S., Minna, J.D., Muller, C.Y. Reproductive Sciences 2007 14 (1) 20-28
Simplifying the preevacuation testing strategy for patients with molar pregnancy.
Knowles LM, Drake RD, Ashfaq R, Castrillon DH, Miller DS, Schorge JO The Journal of reproductive medicine 2007 Aug 52 8 685-8
Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.
Bull-Phelps SL, Garner EI, Walsh CS, Gehrig PA, Miller DS, Schorge JO Gynecologic oncology 2007 Nov 107 2 316-9
Gynecologic oncology group trials in uterine corpus malignancies: recent progress.
Miller DS, King LP Journal of gynecologic oncology 2008 Dec 19 4 218-22
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO Gynecologic oncology 2008 Jul 110 1 65-70
Pharmacotherapy of endometrial cancer.
Barrena Medel NI, Bansal S, Miller DS, Wright JD, Herzog TJ Expert opinion on pharmacotherapy 2009 Aug 10 12 1939-51
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS, Blessing JA, Drake RD, Higgins R, McMeekin DS, Puneky LV, Krasner CN Gynecologic oncology 2009 Dec 115 3 443-6
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer.
Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, Huang TH Cancer research 2009 Dec 69 23 9038-46
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Jun 27 16 2686-91
Recent progress: gynecologic oncology group trials in uterine corpus tumors.
King LP, Miller DS Reviews on recent clinical trials 2009 May 4 2 70-4
Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer.
Miller DS, Fleming G, Randall ME Journal of the National Comprehensive Cancer Network : JNCCN 2009 May 7 5 535-41
Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas.
Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, Huang TH Gynecologic oncology 2010 May 117 2 239-47
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS Gynecologic oncology 2011 Apr 121 1 118-21
The role of lymphadenectomy in endometrial cancer.
Kehoe SM, Miller DS Clinical obstetrics and gynecology 2011 Jun 54 2 235-44
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM Gynecologic oncology 2012 Dec 127 3 456-61
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study
Moore DH. Blessing JA. McQuellon RP. Thaler HT. Cella D. Benda J. Miller DS. Olt G. King S. Boggess JF. Rocereto TF. Journal of Clinical Oncology August 2004 22(15) 3113-9
Simplifying the preevacuation testing strategy for patients with molar pregnancy
Knowles, L.M., Drake, R.D., Ashfaq, R., Castrillon, D.H., Miller, D.S., Schorge, J.O. The Journal of reproductive medicine August 2007 52 (8) 685-688
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study
Long HJ 3rd. Bundy BN. Grendys EC Jr. Benda JA. McMeekin DS. Sorosky J. Miller DS. Eaton LA. Fiorica JV. Journal of Clinical Oncology July 2005 23(21) 4626-33
Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
Miller, D.S., Blessing, J.A., Bodurka, D.C., Bonebrake, A.J., Schorge, J.O. Gynecologic Oncology July 2008 110(1) 65-70
Implications of EGFR inhibition in ovarian cancer cell proliferation
Bull Phelps, S.L., Schorge, J.O., Peyton, M.J., Shigematsu, H., Xiang, L.-L., Miller, D.S., Lea, J.S. Gynecologic Oncology June 2008 109(3) 411-7
Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix
Bull-Phelps, S.L., Garner, E.I.O., Walsh, C.S., Gehrig, P.A., Miller, D.S., Schorge, J.O. Gynecologic Oncology November 2007 107 (2) 316-319
Prognostic factors in gestational trophoblastic tumors: a proposed new scoring system based on multivariate analysis.
Lurain JR, Casanova LA, Miller DS, Rademaker AW American journal of obstetrics and gynecology 1991 Feb 164 2 611-6
The role of contraception in the development of postmolar gestational trophoblastic tumor.
Deicas RE, Miller DS, Rademaker AW, Lurain JR Obstetrics and gynecology 1991 Aug 78 2 221-6
Flow cytometric evaluation of epithelial ovarian cancer.
Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR American journal of obstetrics and gynecology 1990 Jun 162 6 1584-90; discussion 1590-2
A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma.
Miller DS, Ballon SC, Teng NN, Seifer DB, Soriero OM Cancer 1986 Feb 57 3 530-5
Pulsatile administration of low-dose gonadotropin-releasing hormone. Ovulation and pregnancy in women with hypothalamic amenorrhea.
Miller DS, Reid RR, Cetel NS, Rebar RW, Yen SS JAMA : the journal of the American Medical Association 1983 Dec 250 21 2937-41
Tumor size in endometrial cancer.
Schink JC, Rademaker AW, Miller DS, Lurain JR Cancer 1991 Jun 67 11 2791-4
Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-Based Analysis.
Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A Urology 2017 Oct
A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study.
Miller DS, Brady MF, Barrett RJ American journal of clinical oncology 1992 Apr 15 2 125-8
Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer.
Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN Cancer 1992 Jan 69 2 502-10
Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine for the treatment of metastatic, high-risk gestational trophoblastic disease.
Schink JC, Singh DK, Rademaker AW, Miller DS, Lurain JR Obstetrics and gynecology 1992 Nov 80 5 817-20
Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J Gynecologic oncology 2002 Jun 85 3 507-10
Abdominal compartment syndrome in gynecologic surgery.
von Gruenigen VE, Coleman RL, King MR, Miller DS Obstetrics and gynecology 1999 Nov 94 5 Pt 2 830-2
DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases.
Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR Gynecologic oncology 1993 Jul 50 1 20-4
Adenovirus-based p53 gene therapy in ovarian cancer.
Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA, Miller DS, Mathis JM Gynecologic oncology 1995 Nov 59 2 171-8
Classification and staging of gestational trophoblastic tumors.
Miller DS, Lurain JR Obstetrics and gynecology clinics of North America 1988 Sep 15 3 477-90
Transfusion medicine in obstetrics and gynecology.
Santoso JT, Lin DW, Miller DS Obstetrical & gynecological survey 1995 Jun 50 6 470-81
Fluorescence imaging study of organic anion transport from renal proximal tubule cell to lumen.
Miller DS, Letcher S, Barnes DM The American journal of physiology 1996 Sep 271 3 Pt 2 F508-20
In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.
von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM Gynecologic oncology 1998 Jun 69 3 197-204
Frequent expression of beta-human chorionic gonadotropin (beta-hCG) in squamous cell carcinoma of the cervix.
Hameed A, Miller DS, Muller CY, Coleman RL, Albores-Saavedra J International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1999 Oct 18 4 381-6
Uterine metastasis from a heterologous metaplastic breast carcinoma simulating a primary uterine malignancy.
Sinkre P, Milchgrub S, Miller DS, Albores-Saavedra J, Hameed A Gynecologic oncology 2000 Apr 77 1 216-8
Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas.
Tait DL, Miller DS Texas medicine 1997 Jan 93 1 89-91
Ectopic production and localization of beta-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: a case report.
Coleman RL, Lindberg G, Muller CY, Miller DS, Hameed A International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2000 Apr 19 2 179-82
Reply to W.A.A. Tjalma and J.S. Grossman.
Monk BJ, Miller DS, Tewari KS Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Feb
Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients.
Von Gruenigen VE, Coleman RL, Li AJ, Heard MC, Miller DS, Hemsell DL Obstetrics and gynecology 2000 Jul 96 1 23-7
Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study.
O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS Gynecologic oncology 2000 Nov 79 2 238-43
Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants.
Sherwood JB, Shivapurkar N, Lin WM, Ashfaq R, Miller DS, Gazdar AF, Muller CY Gynecologic oncology 2000 Oct 79 1 90-6
Endocrinologic aspects of gestational trophoblastic diseases.
Miller DS, Seifer DB International journal of fertility 1990 May-Jun 35 3 137-53
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment.
Peña CG, Nakada Y, Saatcioglu HD, Aloisio GM, Cuevas I, Zhang S, Miller DS, Lea JS, Wong KK, DeBerardinis RJ, Amelio AL, Brekken RA, Castrillon DH The Journal of clinical investigation 2015 Sep
Clinical Evidence: Metastases can Metastasize.
Stanley GA, Balani JP, Miller DS, Mansour JC, Schwarz RE World journal of oncology 2012 Jun 3 3 138-141
Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE Gynecologic oncology 2001 Nov 83 2 383-7
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Miller DS, Blessing JA, Lentz SS, Waggoner SE Gynecologic oncology 2002 Dec 87 3 247-51
Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study.
Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL American journal of obstetrics and gynecology 2003 Mar 188 3 640-4
Postmolar surveillance at a trophoblastic disease center that serves indigent women.
Allen JE, King MR, Farrar DF, Miller DS, Schorge JO American journal of obstetrics and gynecology 2003 May 188 5 1151-3
Management of low-risk gestational trophoblastic neoplasia in indigent women.
Schorge JO, Lea JS, Farrar DF, King MR, Coleman RL, Miller DS The Journal of reproductive medicine 2003 Oct 48 10 780-4
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Miller DS, Blessing JA, Lentz SS, McMeekin DS Cancer 2003 Oct 98 8 1664-9
P16 as a molecular biomarker of cervical adenocarcinoma.
Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R American journal of obstetrics and gynecology 2004 Mar 190 3 668-73
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A Gynecologic oncology 2004 Feb 92 2 639-43
Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.
Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO Gynecologic oncology 2002 Jan 84 1 115-9
Abnormalities of fragile histidine triad genomic and complementary DNAs in cervical cancer: association with human papillomavirus type.
Muller CY, O'Boyle JD, Fong KM, Wistuba II, Biesterveld E, Ahmadian M, Miller DS, Gazdar AF, Minna JD Journal of the National Cancer Institute 1998 Mar 90 6 433-9
Topotecan in the treatment of gynecologic cancer.
Coleman RL, Miller DS Seminars in oncology 1997 Dec 24 6 Suppl 20 S20-55-S20-63
Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium.
Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS Obstetrics and gynecology 1991 Jul 78 1 63-9
Epithelial ovarian carcinoma in patients with intersex disorders: the role of pituitary gonadotropins in ovarian tumorigenesis.
Miller DS, Teng NN, Ballon SC Gynecologic oncology 1986 Jul 24 3 299-308
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Aug 22 15 3113-9
The effect of naproxen on fever in patients with advanced gynecologic malignancies.
Economos K, Lucci JA, Richardson B, Yazigi R, Miller DS Gynecologic oncology 1995 Feb 56 2 250-4
Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery.
Miller DS Cancer 2017 Jan 123 2 192-196
Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis.
Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY American journal of obstetrics and gynecology 2004 Mar 190 3 674-9
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer.
Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC Clinical cancer research : an official journal of the American Association for Cancer Research 2004 May 10 10 3474-8
A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) women with locally advanced cervical cancer (CXCA): A GOG study.
Moore KN, Sill M, Miller DS, Disilvestro P, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 15_suppl 5032
A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK Gynecologic oncology 2014 Oct
Surgical and systemic management of endometrial cancer: an international survey.
Fotopoulou C, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, Miller DS, Marth C, Fujii S, Sehouli J Archives of gynecology and obstetrics 2014 Oct
Ovarian involvement in endometrioid adenocarcinoma of uterus.
Lin KY, Miller DS, Bailey AA, Andrews SJ, Kehoe SM, Richardson DL, Lea JS Gynecologic oncology 2015 Jul
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.
Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB Gynecologic oncology 2016 Aug
Factors influencing primary treatment of midline vulvar cancers.
Conrad LB, Conrad SA, Miller DS, Richardson DL, Kehoe S, Lea JS Gynecologic oncology 2016 May
The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience.
Manders DB, Sims TT, Bailey A, Hwang L, Richardson DL, Miller DS, Kehoe SM, Albuquerque KV, Lea JS American journal of clinical oncology 2018 May
Adjuvant External Radiation Impacts Outcome of Pelvis-limited Stage III Endometrial Carcinoma: A Multi-institutional Study.
Albuquerque K, Folkert M, Mayadev J, Christie A, Liotta MR, Nagel C, Sevak P, Harkenrider MM, Lea JS, Hanna RK, Small WC, Miller DS, Xie XJ, Potkul RK, Elshaikh MA American journal of clinical oncology 2017 Feb
Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity.
Manders DB, Kehoe SM, Miller DS, Lea JS, Richardson DL American journal of clinical oncology 2017 Feb
Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
Creasman WT, Ali S, Mutch DG, Zaino RJ, Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl ML, Lele SB, Guntupalli SR, Waggoner S, Spirtos N, Boggess JF, Edwards RP, Filiaci VL, Miller DS Gynecologic oncology 2017 Apr
Long-Term Percutaneous Nephrostomy Management of Malignant Urinary Obstruction: Estimation of Optimal Exchange Frequency and Estimation of the Financial Impact of Patient Compliance.
McDevitt JL, Acosta-Torres S, Zhang N, Hu T, Odu A, Wang J, Xi Y, Lamus D, Miller DS, Pillai AK Journal of vascular and interventional radiology : JVIR 2017 Apr
Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.
Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS Obstetrics and gynecology 2016 Sep 128 3 535-42
Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment.
Manders DB, Morón A, McIntire D, Miller DS, Richardson DL, Kehoe SM, Albuquerque KV, Lea JS American journal of clinical oncology 2016 Jun
Adnexal masses requiring surgical intervention in women with advanced cervical cancer.
Nagel CI, Thomas SK, Richardson DL, Kehoe SM, Miller DS, Lea JS Gynecologic oncology 2014 Jul
Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy.
Boren TP, Carrick K, Kehoe SM, Lea J, Miller DS, Richardson DL Gynecologic oncology 2012 Mar 124 3 508-11
New therapies for advanced, recurrent, and metastatic endometrial cancers.
Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS Gynecologic oncology research and practice 2017 4 19
Third-line salvage chemotherapy for recurrent cervical cancer.
Manders DB, Purinton SC, Lea J, Miller DS, Kehoe SM, Richardson DL Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 15_suppl e15510
Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS American journal of clinical oncology 2017 Aug
Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.
Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A Urologic oncology 2017 Dec
A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Miller DS, Blessing JA, Krasner CN, Drake RD, Higgins R, McMeekin DS, Puneky LV Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 15_suppl e16507
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ Gynecologic oncology 2017 Nov
Other primary malignancies in patients with uterine corpus malignancy.
Delin JB, Miller DS, Coleman RL American journal of obstetrics and gynecology 2004 May 190 5 1429-31
A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK Cancer 2004 Feb 100 4 859-68
Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL Gynecologic oncology 2004 Aug 94 2 320-4
Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature.
Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K Archives of pathology & laboratory medicine 2003 Jul 127 7 879-82
Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.
Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2003 Dec 91 3 558-62
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.
Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2002 Oct 87 1 129-32
Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.
Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO Gynecologic oncology 2002 Feb 84 2 285-8
Optimum screening interventions for gynecologic malignancies.
Lea JS, Miller DS Texas medicine 2001 Feb 97 2 49-55
Adenomyofibroma of the endometrium with skeletal muscle differentiation.
Sinkre P, Miller DS, Milchgrub S, Hameed A International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2000 Jul 19 3 280-3
Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor.
Sinkre P, Albores-Saavedra J, Miller DS, Copeland LJ, Hameed A International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2000 Apr 19 2 127-32
Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer.
Von Gruenigen VE, O'Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 1999 Sep 9 5 365-372
Role of TSG101 in uterine cervix cancer.
O'Boyle JD, Proctor ML, Fong KM, Lin WM, Miller DS, Muller CY Gynecologic oncology 1999 Dec 75 3 401-5
Flow cytometric evaluation of early invasive cervical cancer.
Connor JP, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR Obstetrics and gynecology 1993 Mar 81 3 367-71
Study of the selective cytotoxic properties of cationic, lipophilic mitochondrial-specific compounds in gynecologic malignancies.
Christman JE, Miller DS, Coward P, Smith LH, Teng NN Gynecologic oncology 1990 Oct 39 1 72-9
The use of the laser in gynecology.
Miller DS Journal of the South Carolina Medical Association (1975) 1983 Nov 79 11 627-30
Urinary bladder cancer.
Wai CY, Miller DS Clinical obstetrics and gynecology 2002 Sep 45 3 844-54
Prognostic Significance of Nodal Location in Stage IIIC Endometrial Carcinoma: Implications for Optimal Adjuvant Therapy.
Mayadev JS, Elshaikh MA, Christie A, Nagel C, Khan N, Kennedy V, Lea J, Ghanem A, Miller DS, Xie XJ, Folkert M, Albuquerque KV International journal of radiation oncology, biology, physics 2016 Oct 96 2S E303
Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population.
Davidson BA, Nagel CI, Richardson DL, Kehoe SM, Miller DS, Lea JS The Journal of reproductive medicine 2015 May-Jun 60 5-6 243-8
Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.
Felix AS, Brasky TM, Cohn DE, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Deng W, Miller DS, Brinton LA International journal of cancer 2017 Oct
Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer.
Conrad LB, Awdeh H, Acosta-Torres S, Conrad SA, Bailey AA, Miller DS, Lea JS Journal of surgical oncology 2018 Feb
Emphasis on Systemic Therapy in Women With Pelvic Bone Metastasis at Time of Diagnosis of Cervical Cancer.
Manders DB, Sims TT, Albuquerque KV, Carlson MJ, Richardson DL, Kehoe SM, Miller DS, Lea JS American journal of clinical oncology 2018 Mar
Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS, Ashfaq R, Muneer S, Burbee DG, Miller DS, Minna JD, Muller CY Journal of the Society for Gynecologic Investigation 2004 Jul 11 5 329-37
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.
Miller DS, Blessing JA, Kilgore LC, Mannel R, Van Le L American journal of clinical oncology 2000 Aug 23 4 355-7
Agglutinating antibodies to Toxoplasma gondii in sera from captive eastern barred bandicoots in Australia.
Miller DS, Mitchel GF, Biggs B, McCracken H, Myroniuk P, Hewish M Journal of wildlife diseases 2000 Apr 36 2 213-8
Preinvasive and invasive breast and cervical cancer prior to or during pregnancy.
Shivvers SA, Miller DS Clinics in perinatology 1997 Jun 24 2 369-89
Immunologic characterization of tumor markers in human ovarian cancer cell lines.
Kutteh WH, Miller DS, Mathis JM Journal of the Society for Gynecologic Investigation 1996 Jul-Aug 3 4 216-22
Dual-parameter flow cytometric analysis coupling the measurements of forward-angle light scatter and DNA content of archival ovarian carcinomas of low malignant potential.
Eriksen B, Miller DS, Murad TM, Lurain JR, Bauer KD Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1991 Feb 13 1 45-53
Quantitative protein changes in metastatic versus primary epithelial ovarian carcinoma.
Lawson SR, Latter G, Miller DS, Goldstein D, Naps M, Burbeck S, Teng NN, Zuckerkandl E Gynecologic oncology 1991 Apr 41 1 22-7
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.
Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Oct JCO1800454
- Duration of human chorionic gonadotropin surveillance for partial hydatidiform moles.
- Reconstructive pelvic surgery
- Gynecologic Oncology
- Clinical trials
- Antineoplastic drug development
- Gynecologic Cancers
- Surgical Treatment for Gynecologic Cancer
- Medical Treatment of Gynecologic Cancer
- Ovarian Cancer
- Peritoneal Cancer
- Gestational Trophoblastic Disease
- Endometrial Cancer
- Uterine Cancer
- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer